NCT02784171 2024-12-10Pembrolizumab in Patients With Advanced Malignant Pleural MesotheliomaCanadian Cancer Trials GroupPhase 2/3 Completed520 enrolled 16 charts 1 FDA
NCT01907100 2019-03-18Nintedanib (BIBF 1120) in MesotheliomaBoehringer IngelheimPhase 2/3 Terminated545 enrolled 15 charts